CAR immune cells: design principles, resistance and the next generation
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating
M Hamieh, J Mansilla-Soto, I Rivière, M Sadelain - Cancer Discovery, 2023 - AACR
The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …
Cooperative CAR targeting to selectively eliminate AML and minimize escape
S Haubner, J Mansilla-Soto, S Nataraj, F Kogel… - Cancer cell, 2023 - cell.com
Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …
Rethinking cancer targeting strategies in the era of smart cell therapeutics
In the past several decades, the development of cancer therapeutics has largely focused on
precision targeting of single cancer-associated molecules. Despite great advances, such …
precision targeting of single cancer-associated molecules. Despite great advances, such …
Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
NJ Bangayan, L Wang, G Burton Sojo… - Proceedings of the …, 2023 - National Acad Sciences
CAR (chimeric antigen receptor) T cell therapy has shown clinical success in treating
hematological malignancies, but its treatment of solid tumors has been limited. One major …
hematological malignancies, but its treatment of solid tumors has been limited. One major …
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells
AR Haas, RJ Golden, LA Litzky, B Engels, L Zhao… - Molecular Therapy, 2023 - cell.com
Multiple clinical studies have treated mesothelin (MSLN)-positive solid tumors by
administering MSLN-directed chimeric antigen receptor (CAR) T cells. Although these …
administering MSLN-directed chimeric antigen receptor (CAR) T cells. Although these …
Single-cell analysis of target antigens of CAR-T reveals a potential landscape of “on-target, off-tumor toxicity”
Y Zhang, Y Li, W Cao, F Wang, X **e, Y Li… - Frontiers in …, 2021 - frontiersin.org
Cellular immunotherapy represented by CD19-directed chimeric antigen receptor T (CAR-T)
cells has achieved great success in recent years. An increasing number of CAR-T therapies …
cells has achieved great success in recent years. An increasing number of CAR-T therapies …
Emerging CAR T cell strategies for the treatment of AML
Simple Summary Chimeric antigen receptors (CARs) targeting CD19 have emerged as a
new treatment for hematological malignancies. As a “living therapy”, CARs can precisely …
new treatment for hematological malignancies. As a “living therapy”, CARs can precisely …
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high
mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the …
mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the …